ITV reality star rushed to A&E as she shares worrying hospital bed snaps
HOSPITAL DASH
The star has been taken to hospital for septal surgery
REAL Housewives of Cheshire star Leilani Dowding has been taken to hospital for surgery.
The 45-year-old reality star and model shared pictures and a video from her hospital bed on X (formerly Twitter), giving an update on her current condition.
3
Leilani revealed that she has had to have functional endoscopic sinus surgery (FESS) as well as a septoplasty, which realigns the septum in your nose.
The star shared a picture and videos of her nose taped up with bloody bandages as she spoke.
"Thanks for all the get well wishes … not had an accident .. not had mouth sewn up yet," she joked.
"Just had an op on my sinus. Haven't been able to breathe for a while and being a mouth breather isn't fun…
"it's also smelly as it was full of pus.. should be home later today."
3
3
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Telegraph
11 minutes ago
- Telegraph
Robbie Williams, Murrayfield Stadium, review: The most spectacular end-of-the-pier show ever seen
'Allow me to reintroduce myself!' yelled the squat, muscular, tattooed, silver haired 51-year-old, standing on a runway in the centre of the vast Murrayfield Stadium in Edinburgh, Scotland, a tiny, isolated figure in the midst of a 70,000 strong crowd. 'My name is ROBBIE! F______! WILLIAMS!' And the crowd roared back with a gusty, noisy delight to match the star's own. He's back, folks. To be fair, I am not sure how far he ever really went away, but Britain's self-proclaimed 'King of Entertainment' is on the march, determined to reclaim his crown. Oasis mania is about to be unleashed once more in the UK, as the biggest band in Britpop returns to the stage next month. Cheekily stealing their thunder, they are being preceded around Britain's stadiums by the biggest British hitmaker of the 1990s and 2000s in a show mischievously entitled Britpop, filled with buzzing guitars and mighty singalongs. Mind you, that's where any resemblance to the fiercely dour and belligerently stationary Oasis ends. Because Williams throws everything he's got at his audience – special effects, jokes, choreography, stunts and, mainly, himself – in a relentless, almost desperate desire to please. His spectacular show opened with a gasp-inducing high dive from a giant winged platform suspended above the stage and ended two hours later with fans singing the choruses of Williams's beloved ballad Angels louder than the giant PA, whilst the star of the occasion looked on beaming with emotional delight. I am not sure who was more moved by Williams's relentless antics – the woman named Debbie from Dundee openly weeping as Williams clambered into the crowd to serenade her with a version of She's The One, or Williams himself as he basked in the glow of love and acceptance. A neurotic neediness is at the heart of Williams's appeal but is crucially wrapped up in songs with meaningful lyrics, flowing melodies, snappy hooks and huge choruses that the audience seem even more eager to sing than the performer. Indeed, it is not really a criticism, but Williams talks as much as he sings, frequently interrupting his own emotional performances with silly jokes and overexcited chatter. 'I'm s_______ hits all over the place!' he shouts in the middle of an otherwise gorgeous A Love Supreme and makes a lewd penis joke during his most vulnerable anthem Come Undone. A Robbie Williams show is a lot to take in. It's an end of the pier cabaret routine staged with the firepower of a Hollywood blockbuster; a cheesy pop extravaganza infused with darkly witty postmodern irony; an exposed bundle of raw human neuroses transposed into monster pop anthems interlaced with old fashioned showbiz comedy patter and interrupted by scatological stream of consciousness babble. He makes unscripted comments about age ('I'm 51,' he repeatedly shouted in self-amazement), anxiety ('I've been s_______ myself for weeks, old feelings from Take That, PTSD'), his family ('my mum has dementia, and my dad has Parkinson's, I feel like I'm in sniper's alley'), and sings the showbiz standard My Way in a pink suit and boa with all the feeling of a man who can't quite believe he's made it this far. He's 51, you know. There is a theme to proceedings, roughly hovering around the question of 'what is entertainment?'. Williams offers himself as the answer to his own question, to which the crowd offer noisy validation. From the riotous bombast of Let Me Entertain You to the vulnerability of anthemic ballad Feel, Williams arrived fully armed with the singalong hits that his massive audience have already taken to heart. In his natural element on stage, he put them across with a combination of ridiculous humour, raw humanity and powerful musicality that proved irresistible. We let him entertain us. I suspect from his gurning delight that the experience was mutual.
Sky News
14 minutes ago
- Sky News
'Transformational' new drug could stop breast cancer tumours before they grow, trial finds
A new drug could stop some breast cancer tumours from using hormones to grow, a trial has found. Results from the Serena-6 trial, carried out with the Institute of Cancer Research in London, suggest that using camizestrant could help patients stay well longer and delay the need for chemotherapy. According to Cancer Research UK, the drug works by blocking oestrogen from getting into the breast cancer cell, which researchers hope can then stop or slow the growth of cancer. Breast cancer patients given the drug in the trial reduced their chances of the disease progressing by 52% compared to standard therapies. Professor Kristian Helin, chief executive of the Institute of Cancer Research, said the results "represent more than a clinical milestone, they represent a transformational shift in how we approach precision medicine". Co-principal investigator Professor Nick Turner also called the development of the drug "a pivotal moment in breast cancer care". 1:48 The study, funded by AstraZeneca, looked at patients with hormone-positive, HER2-negative breast cancer - about 70% of cases. More than 3,000 patients from 23 countries took part in phase three of the trial, which saw doctors use blood tests to detect changes in the cancer's DNA to see which treatments were ineffective. For those taking camizestrant, their cancer stabilised for around 16 months on average, compared with about nine months for other treatments. However, 1% of patients taking the new drug stopped taking it because of side effects. Further results from the Serena-6 trial will be presented at the American Society of Clinical Oncology annual meeting in Chicago on Sunday. Cancer Research UK reports that breast cancer is the most common type of the disease, with around 56,400 women and around 390 men diagnosed in the UK each year. The trial was also the first worldwide study to show that using blood tests to find early signs of cancer resistance to treatment helps patients. Dr Catherine Elliott, director of research at Cancer Research UK, praised the breakthrough as a "clear example of how blood tests are starting to transform cancer treatment". "By tracking tiny traces of tumour DNA in the blood, researchers were able to spot early signs of treatment resistance and switch therapies before cancer had a chance to grow," she added. "It shows how circulating tumour DNA, or ctDNA, could help doctors make smarter, more timely treatment decisions. "This approach could become an important part of how we personalise care for people with advanced breast cancer."
Daily Mail
18 minutes ago
- Daily Mail
Major discovery about 'invisible' breast tumours that are too small to show up on scans
Thousands of women have been thrown a lifeline thanks to a 'next generation' drug that can destroy breast cancer tumours, months before they even grow. The daily pill, known as camizestrant, stops cancer cells from developing, slowing the spread of the disease and delaying the need for gruelling chemotherapy. Around seven in ten breast cancer patients in the UK have a type of the disease known as HR positive HER-2 negative breast cancer—the most common form. Of these, around 40 per cent can develop an aggressive genetic mutation that makes their outlook incredibly bleak. But the 'transformational' trial found patients given the drug camizestrant saw their risk of the cancer progressing slashed by more than half. It was also the first worldwide study that showed blood tests, rather than scans, can pick up early signs of cancer returning. Doctors first used the test, known as a liquid biopsy, to spot changes in the cancer's DNA—when they found signs of an ESR1 mutation, some patients were given camizestrant, while others stayed on their usual treatment. Experts presenting the findings today at the American Society for Clinical Oncology conference (ASCO) in Chicago, hailed it a 'pivotal moment in breast cancer care' and 'truly fundamental shift in how we approach cancer'. The drug is already being fast-tracked for use in the US and has been sent for approval in the UK. Professor Nicholas Turner, an expert in molecular oncology at The Institute of Cancer Research, London and the Royal Marsden NHS Foundation Trust, who co-led the major trial, said: 'This is a pivotal moment in breast cancer care. 'This proactive approach also redefines how we think about drug resistance in this type of breast cancer. 'This is a potential new treatment strategy in oncology to treat developing resistance before it causes disease progression.' Professor Kristian Helin, chief executive of The Institute of Cancer Research, London, added: 'The results represent more than a clinical milestone—they represent a transformational shift in how we approach precision medicine. 'It is very exciting to see this technology being used to delay disease progression in patients and extend the benefits of treatment in patients with this type of advanced breast cancer and delay the need for chemotherapy for as long as possible. 'These breakthroughs are helping shape personalised breast cancer treatment, allowing doctors to adjust therapies earlier and improve patient outcomes.' In the trial, 3,325 patients HR positive HER-2 negative advanced breast cancer from 23 countries were screened for ESR1 mutations using a liquid biopsy every eight to 12 weeks. Of these, 315 women who tested positive for an ESR1 mutation were given either AstraZeneca's camizestrant and a medicine known as a CDK4/6 inhibitor or another hormone therapy as well as a CDK4/6 inhibitor. Researchers found those on the camizestrant combination slashed their risk of death or the cancer progressing by 56 per cent. The drug also kept the cancer at bay for 16 months on average compared to 9.2 months on standard treatment. Just one per cent of patients stopped taking the drug over side effects. Presenting the findings at ASCO, Susan Galbraith, executive vice president of oncology at AstraZeneca said the drug had now been given 'breakthrough therapy designation' by the Food and Drugs Administration in the US, helping to speed up regulatory review. 'We are having ongoing discussions with regulatory authorities including the UK', added. Dave Fredickson, AstraZeneca's executive vice president of oncology business unit, also said the drug demonstrated a 'truly fundamental shift in how we approach cancer care. 'We're moving away from a one size fits all era and targeting cancer early.' Meanwhile, Dr Catherine Elliott, director of research at Cancer Research UK, said: 'This study is a clear example of how blood tests are starting to transform cancer treatment. 'By tracking tiny traces of tumour DNA in the blood, researchers were able to spot early signs of treatment resistance and switch therapies before cancer had a chance to grow. 'It shows how circulating tumour DNA—or ctDNA—could help doctors make smarter, more timely treatment decisions. 'This approach could become an important part of how we personalise care for people with advanced breast cancer.'
